<DOC>
	<DOCNO>NCT00776217</DOCNO>
	<brief_summary>To compare single-dose oral bioavailability loratadine 10 mg orally disintegrate tablet Ohm Laboratories ( subsidiary Ranbaxy Pharmaceuticals Inc. , USA ) Claritin速 Reditabs速 ( contain loratadine 10 mg ) Schering-Plough Healthcare Product Inc. , USA healthy , adult , human male subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions</brief_title>
	<detailed_description>The study conduct open label , balance , randomize , two-treatment , two-sequence , two-period , single-dose , crossover , bioavailability study loratadine formulation compare loratadine 10 mg orally disintegrate tablet Ohm Laboratories , Inc. ( subsidiary Ranbaxy pharmaceutical Inc , USA ) Claritin速 Reditabs速 10 mg tablet ( contain loratadine 10 mg ) Schering- Plough Healthcare Product Inc , healthy , adult , male , human subject fast condition . A single oral dose loratadine 10 mg orally disintegrate tablet orally administer low light condition period study supervision train Medical Officer . Subjects instructed let tablet completely dissolve tongue swallowing saliva , 240 mL water administer 30 second drug administration . During course study safety parameter assess vital sign , clinical examination , medical history clinical laboratory safety test ( hematology , biochemical parameter urine analysis ) baseline . Laboratory parameter hematology biochemistry repeat end study . A total 80 subject randomize receive single oral dose test reference formulation loratadine 10 mg. Seventy-four subject complete period study .</detailed_description>
	<mesh_term>Loratadine</mesh_term>
	<criteria>Aged 1845 year . Were neither overweight underweight correspond height per Life Insurance Corporation India height/weight chart nonmedical case . Had voluntarily give write informed consent participate study . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . Had history allergy loratadine . Had history hypertension . Had evidence organ dysfunction clinically significant deviation normal , physical clinical determination . Had history serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological hematological disease , diabetes glaucoma . Had presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . Had presence value significantly different normal reference range and/or judge clinically significant hemoglobin , total white blood cell count , differential WBC count platelet count . Was positive urinary screen test drug abuse ( opiates cannabinoids ) Had presence value significantly different normal reference range and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . Had clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . Had clinically abnormal ECG Chest Xray . Had history psychiatric illness , might impair ability provide write informed consent Was regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . Had history drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . Used enzyme modify drug within 30 day prior Day 1 study . Had participate clinical trial within 12 week precede Day 1 study . Subjects , completion study , donate and/or lose 350 mL blood past 3 month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>bioequivalence loratadine 10 mg orally disintegrate tablet fast</keyword>
</DOC>